Glucorell, Anafit settle FTC deceptive advertising claims
WASHINGTON Two marketers of dietary supplements that purportedly prevented and treated diabetes have settled Federal Trade Commission charges that they engaged in deceptive advertising practices, FTC reported Thursday.
According to the FTC’s complaint, GlucorelFTCd and Anafit, both based in Orlando, Fla., made false and unsubstantiated claims that two dietary supplements, Insulow and Glucorell R, were effective for preventing and treating diabetes.
The order contains a judgment of $493,545, which is the total amount the defendants received in sales for Glucorell R and Insulow between January 2005 and May 2008. However, the entire judgment is suspended due to their inability to pay. If it is determined that the financial information given to the FTC was untruthful, then the full amount of the judgment will automatically become due.
Along with statements in their ads such as “Insulow may be the only thing between you … and a needle,” the defendants also made unsubstantiated claims that Insulow prevents or reduces the risk of developing Type 2 diabetes, is an effective treatment for Type 1 and Type 2 diabetes, lowers high blood sugar levels, prevents or reverses insulin resistence, increases fat loss and decreases insulin-related obesity and enables diabetics to reduce or eliminate the amount of drugs and insulin required to keep blood sugar levels healthy and reduce insulin resistance, according to the complaint. The FTC also alleged that the defendants falsely advertised that all of these claims except the last had been proven by clinical studies.
For Glucorell R, the defendants’ advertisements allegedly claimed that Glucorell R is effective for treating Type 2 diabetes, prevents or reduces the risk of developing Type 2 diabetes and is effective in treating and preventing cancer. According to the complaint, the defendants also falsely advertised that the last two Glucorell R claims were proven by clinical studies.
According to papers filed with the court, Glucorell has been primarily responsible for packaging, distributing and selling Insulow, and has marketed both supplements; while Anafit has been responsible for packaging, distributing, selling and marketing only Glucorell R.
Schiff announces start-up networking site for active adults
SALT LAKE CITY Schiff Nutrition International officially announced Thursday the formulation of the Move Free Advanced Active Adults Club, a nationwide network of adults aged 50 and above who are committed to remaining active, physically fit and knowledgeable through their golden years.
MFAAAC is already comprised of more than 1,000 seniors who have opted-in to provide feedback on topics of interest to older adults, receive health information on natural supplements to ease joint discomfort, and tell their inspirational stories of self-expression, passion and age defying feats.
“We have received an overwhelming response from adults who want to share their story after trying Move Free Advanced, and here at Schiff we want to acknowledge and thank those individuals,” Luke Bucci, vice president of research at Schiff said. “We look forward to hearing from even more active adults across the country, and encourage people to share their success stories with us.”
To become a MFAAAC member, consumers can either sign up at www.keepmovingwithmovefree.com or call the Move Free Advanced Advocates Hotline at 866-914-2082 to receive a free 7-day starter. At times, members are asked to be a resource and provide feedback on their active adult lifestyle. There is no fee to join.
Home Diagnostics searches for new president, CEO
FORT LAUDERDALE, Fla. Home Diagnostics on Thursday announced that the board of directors has retained the executive search firm DavenportMajor to recruit a successor to J. Richard Damron, president and chief executive officer, who will be departing the company following a transition to the new president and chief executive officer.
Damron will remain in his present role until a transition is completed, which is expected to be in the first half of 2009.
“We appreciate the dedication that Dick has provided to Home Diagnostics over his eight-year tenure at the Company,” George Holley, chairman of Home Diagnostics, said. “[Damron’s] leadership in growing Home Diagnostics and the transition to public ownership has been invaluable in positioning the Company for future growth and success. We wish him the best in his future endeavors and appreciate his commitment to work with the company through the transition to a successor.”
“Since becoming president, chief executive officer and a director of Home Diagnostics in February 2001, we have achieved a number of major milestones,” Damron said. “With these accomplishments, I believe the company is poised for its next stage of growth and the time is appropriate for me to move on to my next professional challenge.”